Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.

Previous post Constellation Brands books large loss on wine and spirits, but beer sales rise
Next post Why Salesforce’s stock is getting more love from Wall Street analysts lately